Sequana Medical NV Market Cap ($47.76 Million)
Market Cap & Net Worth: Sequana Medical NV (SEQUA)
Sequana Medical NV market cap. Sequana Medical NV (BR:SEQUA) has a market capitalization of $47.76 Million (€40.85 Million) as of November 4, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #21880 globally and #91 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sequana Medical NV's stock price €0.61 by its total outstanding shares 78172033 (78.17 Million). Also see Sequana Medical NV (SEQUA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Sequana Medical NV Market Cap History (2019–2026)
Sequana Medical NV market cap history from 2019 to 2026. Data shows change from $572.11 Million to $55.84 Million (-26.34% CAGR). Check current stock price of Sequana Medical NV for real-time trading data and today's change.
Index Memberships
Sequana Medical NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL Small
BELS
|
$5.75 Billion | 0.83% | #19 of 20 |
|
BEL All Share
BSPT
|
$835.59 Billion | 0.01% | #93 of 108 |
Weight: Sequana Medical NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sequana Medical NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sequana Medical NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sequana Medical NV (SEQUA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2638.28x
Sequana Medical NV's market cap is 2638.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $572.11 Million | $970.64K | -$14.98 Million | 589.42x | N/A |
| 2020 | $1.08 Billion | $963.28K | -$19.11 Million | 1119.53x | N/A |
| 2021 | $690.92 Million | $370.50K | -$23.62 Million | 1864.83x | N/A |
| 2022 | $548.35 Million | $922.69K | -$30.76 Million | 594.29x | N/A |
| 2023 | $365.57 Million | $712.17K | -$32.56 Million | 513.31x | N/A |
| 2024 | $279.66 Million | $106.00K | -$44.65 Million | 2638.28x | N/A |
Competitor Companies of SEQUA by Market Capitalization
Companies near Sequana Medical NV in the global market cap rankings as of November 4, 2026. Also see Sequana Medical NV (SEQUA) total assets for a full breakdown of the balance sheet.
Key companies related to Sequana Medical NV by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Sequana Medical NV (2019–2026)
Market capitalization of Sequana Medical NV from 2019 to today. Between 2019 and today, Sequana Medical NV's market cap moved from $572.11 Million to $ 55.84 Million, with a yearly change of -26.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €55.84 Million | -3.63% |
| 2025 | €57.94 Million | -79.28% |
| 2024 | €279.66 Million | -23.50% |
| 2023 | €365.57 Million | -33.33% |
| 2022 | €548.35 Million | -20.63% |
| 2021 | €690.92 Million | -35.93% |
| 2020 | €1.08 Billion | +88.50% |
| 2019 | €572.11 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Sequana Medical NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.76 Million USD |
| MoneyControl | $47.76 Million USD |
| MarketWatch | $47.76 Million USD |
| marketcap.company | $47.76 Million USD |
| Reuters | $47.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more